Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name
Interested in InSight 2019
Cart
<We_can_help/>

What are you looking for?

<Good_things_happen/> Welcome to Conference

The Neurobiology of Psychedelics: Status and Perspectives for the treatment of affective disorder

oral presentation

Since the 1990s, advances in the mechanism of action psychedelic drugs such as psilocybin and LSD have led the foundation for a renewed interest for their application in the treatment of various psychiatric disorders. Specifically, accumulating evidence from molecular, behavioral and neuroimaging studies suggests that psychedelics acutely modulate emotion regulation, social interaction and the sense of self via neural mechanisms in healthy subjects that are conceptually relevant for the improvement of affective disorders, e.g. depression (Vollenweider and Kometer 2010 1). Accordingly, early psychedelic-assisted psychotherapy studies posit that therapeutic efficacy of psychedelics to improve depression depends on their capacity to weaken self-driven defense mechanisms and to ease emotion processing and memory blocks, and on the subsequent “working through” of resistance and integration of new insight in the therapeutic relationship to enable enduring positive changes (Leuner 1981 2, Rucker et al. 2016 3). A few controlled and an open clinical trial using psilocybin in cancer patients with depression or in major depression have showed now that psilocybin in conjunction with a supportive setting or psychotherapy improves depression and anxiety after only 1-2 doses enduringly for 3-6 month, presumably mediated by the intensity and quality of the mystical-type of experience or the phenomenon of self-dissolution (Ross et al. 2016 4, Griffiths et al. 2016 5, Carhart-Harris et al. 2016 6). In this presentation, I will discuss recent research strategies with psychedelics and advances to identify molecular, cellular, and system-based correlates of psychedelic-induced alterations of the sense of self, emotion processing, and social interactions as relevant for the treatment of depression. Furthermore, I will review the current knowledge on potential predictors shaping the acute and sustained effects of psychedelics in healthy subjects and patients. Notably, a better understanding of the key mechanism of action of psychedelics and of the key predictors of outcome may allow on the long run to fine-tune and tailor psychedelic-assisted therapy models.

Speaker

Date

September 7th 2019

Time

16:15-16:45

Location

Room: Bernhard Von Langenbeck
tickets
Franz X. Vollenweider
Prof. Dr. med., FMH Psych.

Franz X. Vollenweider

Professor of Psychiatry, University of Zurich more about the speaker

Related Events

A comparison of effects and experiences following either vaporization or intramuscular injection of synthetic 5-methoxy-N,N-dimethyltryptamine in a naturalistic setting

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic substance which can be synthetically produced, and found in plants, as well as in the secretion of the Incilius Alvarius toad (also known as Bufo Alvarius). Previous research has demonstrated the prospective therapeutic potential of 5-methoxy-N,N-dimethyltryptamine, however more research is warranted. While the common route of administration appears to be vaporization, intramuscular injection is also being used – but in much lower rates. Furthermore, anecdotal reports online have described a poorly understood phenomenon following use […]

more details

Psilocybin-Assisted Treatment of Alcohol Use Disorder: Historical Context and Current Clinical Research

The use of classic psychedelics in the treatment of alcohol use disorder dates to Hoffer and Osmond’s work with LSD in Saskatchewan starting in 1953. Initially seen as a way to safely induce a delirium tremens-like experience, LSD was tested in clinical trials and used in treatment programs for thousands of patients through the early 1970s, resulting in substantial but inconclusive evidence for its effectiveness. With increasing restriction of access to psychedelics for reach purposes, LSD research ceased in the […]

more details

Psychedelics in context: Psychological, social, and environmental factors in guided group experiences

Legal in many countries, psychedelic ceremonies and retreats offer a structured and supportive environment for an ever increasing group of individuals seeking healing, insight, or personal growth through the use of psychedelics. Yet, little is known about the psychological, social and environmental factors which determine acute and long-term responses to guided psychedelic use outside clinical environments. In order to examine the influence of contextual factors on the acute psychedelic experience and its psychological outcomes, the present study prospectively collected data […]

more details

Conference tickets

With your ticket you will have access to the whole conference - with keynotes, panels, round tables, posters and daylight social events. We will ask for a small extra fee for the Friday evening social program. The pre-conference workshops have to be booked separately and each workshop needs an individual ticket. By clicking on "Book now" below you also have the option to buy your workshop tickets.

*Reduced fees apply to students, cooperation partners as well as unemployed and retired individuals who have a monthly net income below 840,- €. Proof of status will be required.

THE CONFERENCE IS SOLD OUT! Subscribe to our newsletter to become an early bird for 2021!
https://mind-foundation.org/

Catering service

 

With this ticket you can use the catering service all inclusive for three days. The service includes coffee, water, tea and fruit.

Regular

after 14 April 2019

  • Standard €250
  • Reduced €150*
  • MIND members Standard €180
  • MIND members Reduced €90

Philanthropist

 

  • Donate €600 or more
  • Invite a friend/colleague to be your VIP guest at the event

Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name